| Literature DB >> 26872866 |
Simon Boecker1, Sophia Zobel2, Vera Meyer3, Roderich D Süssmuth4.
Abstract
Filamentous fungi have the ability to produce a wide range of secondary metabolites some of which are potent toxins whereas others are exploited as food additives or drugs. Fungal natural products still play an important role in the discovery of new chemical entities for potential use as pharmaceuticals. However, in most cases they cannot be directly used as drugs due to toxic side effects or suboptimal pharmacokinetics. To improve drug-like properties, including bioactivity and stability or to produce better precursors for semi-synthetic routes, one needs to generate non-natural derivatives from known fungal secondary metabolites. In this minireview, we describe past and recent biosynthetic approaches for the diversification of fungal natural products, covering examples from precursor-directed biosynthesis, mutasynthesis, metabolic engineering and biocombinatorial synthesis. To illustrate the current state-of-the-art, challenges and pitfalls, we lay particular emphasis on the class of fungal cyclodepsipeptides which have been studied longtime for product diversification and which are of pharmaceutical relevance as drugs.Entities:
Keywords: Aspergillus; Combinatorial biosynthesis; Metabolic engineering; Mutasynthesis; Precursor-directed biosynthesis; Secondary metabolite
Mesh:
Substances:
Year: 2016 PMID: 26872866 DOI: 10.1016/j.fgb.2016.02.003
Source DB: PubMed Journal: Fungal Genet Biol ISSN: 1087-1845 Impact factor: 3.495